Hyaluronic acid and glucosamine sulfate for adult Kashin-Beck disease: a cluster-randomized, placebo-controlled study.
To evaluate the efficacy and safety of hyaluronic acid (HA) and glucosamine sulfate (GS) in alleviating symptoms and improving function of Kashin-Beck disease (KBD). A cluster-randomized, placebo-controlled trial was conducted in 150 patients with KBD. Participants were randomly allocated to receive intra-articular injection hyaluronic acid (IAHA) for 4 weeks, oral GS for 12 weeks, or oral placebo for 12 weeks. The primary outcome measures were 20 % and 50 % reductions in pain from baseline measured by the Western Ontario and McMaster Universities Osteoarthritis (WOMAC) index. Secondary outcome measures included WOMAC index parameters of pain, stiffness, and physical function. The third outcome measure was mean change in Lequence score. HA and GS were effective in reducing WOMAC pain by 20 % (differences of 43.5 % and 25.4 %) and 50 % (differences of 43.4 % and 26.9 %). Both HA and GS significantly reduced WOMAC pain, WOMAC stiffness, and WOMAC normalized score compared with placebo group (all P < 0.05). IAHA was significantly more effective than oral GS in improving WOMAC normalized score (P = 0.034), pain (P = 0.002), stiffness (P = 0.018), and function (P = 0.044). The results indicate that HA and GS were more effective than placebo in treating KBD and HA was more effective than GS.
Institute of Endemic Diseases of School of Public Health, Health Science Center, Xi'an Jiaotong University, Xi'an, 710061, People's Republic of China.|Key Laboratory of Environment and Genes Related to Diseases, Ministry of Education, Xi'an, 710061, People's Republic of China.|Key Laboratory of Trace elements and Endemic Diseases, Ministry of Health, Xi'an, 710061, People's Republic of China.
Chuan-Tao
CT
Xia
Institute of Endemic Diseases of School of Public Health, Health Science Center, Xi'an Jiaotong University, Xi'an, 710061, People's Republic of China.|Key Laboratory of Environment and Genes Related to Diseases, Ministry of Education, Xi'an, 710061, People's Republic of China.|Key Laboratory of Trace elements and Endemic Diseases, Ministry of Health, Xi'an, 710061, People's Republic of China.
Fang-Fang
FF
Yu
Institute of Endemic Diseases of School of Public Health, Health Science Center, Xi'an Jiaotong University, Xi'an, 710061, People's Republic of China.|Key Laboratory of Environment and Genes Related to Diseases, Ministry of Education, Xi'an, 710061, People's Republic of China.|Key Laboratory of Trace elements and Endemic Diseases, Ministry of Health, Xi'an, 710061, People's Republic of China.
Feng-Ling
FL
Ren
Institute of Endemic Diseases of School of Public Health, Health Science Center, Xi'an Jiaotong University, Xi'an, 710061, People's Republic of China.|Key Laboratory of Environment and Genes Related to Diseases, Ministry of Education, Xi'an, 710061, People's Republic of China.|Key Laboratory of Trace elements and Endemic Diseases, Ministry of Health, Xi'an, 710061, People's Republic of China.
Hua
H
Fang
Institute of Endemic Diseases of School of Public Health, Health Science Center, Xi'an Jiaotong University, Xi'an, 710061, People's Republic of China. guox@mail.xjtu.edu.cn.|Key Laboratory of Environment and Genes Related to Diseases, Ministry of Education, Xi'an, 710061, People's Republic of China. guox@mail.xjtu.edu.cn.|Key Laboratory of Trace elements and Endemic Diseases, Ministry of Health, Xi'an, 710061, People's Republic of China. guox@mail.xjtu.edu.cn.|School of Public Health, Health Science Centre, Xi'an Jiaotong University, No 76 Yanta West Road, Xi'an, Shaanxi, 710061, People's Republic of China. guox@mail.xjtu.edu.cn.
Xiong
X
Guo
D000328:Adult; D000368:Aged; D004311:Double-Blind Method; D005260:Female; D005944:Glucosamine / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D006820:Hyaluronic Acid / Q000009:adverse effects / Q000627:therapeutic use*; D057767:Kashin-Beck Disease / Q000175:diagnosis / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D010147:Pain Measurement; D012720:Severity of Illness Index; D016896:Treatment Outcome
D006820:Hyaluronic Acid; D005944:Glucosamine
Glucosamine sulfate (GS); Hyaluronic acid (HA); Kashin-Beck disease; WOMAC index